^
18h
The Genetic Profile of Large B-Cell Lymphomas Presenting in the Ocular Adnexa. (PubMed, Int J Mol Sci)
Relapsed DLBCL-NOS presenting in the ocular adnexa (n = 6) were all of non-GCB origin and frequently of MCD subtype (n = 3, 50%), presenting with a similar genetic profile as primary ocular adnexal DLBCL-NOS. These results provide valuable insights into genetic drivers in ocular adnexal DLBCL-NOS, offering potential applications in future precision medicine.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • TBL1XR1 (TBL1X Receptor 1)
|
MYC rearrangement • BCL2 rearrangement
23h
Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma. (PubMed, NPJ Precis Oncol)
In assessing data obtained from fine needle biopsies, experiments revealed that there was a higher level of agreement in the quantitative results between Artificial Intelligence (AI) algorithms and pathologists, as well as among pathologists themselves, in comparison to the data obtained from surgical specimens. We highlight that the AI-enabled analytics enhance the objectivity and interpretability of PD-L1 quantification to improve the targeted immunotherapy development in DLBCL patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
1d
TRuST: A Study to Assess the Long-term Safety of Tazemetostat (clinicaltrials.gov)
P1/2, N=100, Enrolling by invitation, Epizyme, Inc. | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
Tazverik (tazemetostat)
1d
Trial completion date
|
Keytruda (pembrolizumab) • pegenzileukin (SAR444245)
1d
Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization. (PubMed, J Clin Exp Hematop)
The 5 cases shared IGHV preferentially used in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in the latter may be different from that of the former.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL3 (BCL3 Transcription Coactivator)
|
MYC expression
1d
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. (PubMed, Blood Adv)
In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), R-CHOP (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21). Grade 3-4 neutropenia and thrombocytopenia events were most frequent with intensive chemoimmunotherapy + venetoclax; grade 3-4 infection rates were similar across treatment groups. In this difficult-to-treat RT patient population, venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in a subset of patients.
Clinical • Journal • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • Rituxan (rituximab)
1d
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients-Case Control Study. (PubMed, Med Sci (Basel))
Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.
Journal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*11
1d
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, J Immunother Cancer)
This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and resistance.
Journal • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
|
CD20 expression
|
odronextamab (REGN1979)
1d
Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview. (PubMed, Hematol Rep)
Treatment approaches are evolving, with chemoimmunotherapy remaining standard for many indolent cases while intensified regimens and targeted agents show promise for refractory or high-risk aggressive disease. Continued elucidation of the genetic and microenvironmental underpinnings of lymphomagenesis is critical for developing personalized therapeutic strategies.
Review • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC translocation
2d
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL (clinicaltrials.gov)
P3, N=475, Active, not recruiting, Fujian Medical University | Recruiting --> Active, not recruiting
Enrollment closed
2d
Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma. (PubMed, Discov Med)
In summary, FLOT2 functions as an oncogene and is linked to DLBCL prognosis and the tumor microenvironment. Targeting FLOT2 deletion emerges as a novel strategy to impede DLBCL aggressiveness by inhibiting cell proliferation and invasion, ultimately inducing apoptotic cell death.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
3d
EPCORE NHL-1: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=666, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | Trial completion date: Apr 2029 --> Jan 2029
Enrollment closed • Trial completion date
|
CD20 positive
|
Epkinly (epcoritamab-bysp)
3d
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL (clinicaltrials.gov)
P=N/A, N=400, Recruiting, AstraZeneca | Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Oct 2024 --> May 2024
Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world
4d
The aryl hydrocarbon receptor differentially modulates the expression profile of antibody isotypes in a human B-cell line. (PubMed, Toxicol Sci)
These results suggest that modulation of AhR activity differentially alters the IgH isotypic expression profile and antibody secretion that may be partly dependent on cellular stimulation. Since a variety of chemicals from anthropogenic, industrial, pharmaceutical, dietary, and bacterial sources bind the AhR, the ability of environmental exposures to alter AhR activity (ie activate or inhibit) may have a direct influence on immune function and antibody-relevant disease conditions.
Preclinical • Journal
|
CD40LG (CD40 ligand) • IL4 (Interleukin 4)
4d
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=40, Recruiting, Novartis Pharmaceuticals | N=124 --> 40 | Trial completion date: Jun 2027 --> Oct 2026 | Trial primary completion date: Jun 2027 --> Oct 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
lenalidomide • ianalumab (VAY736)
5d
Characterization of primary small intestinal lymphoma: a retrospective study based on double balloon endoscopy. (PubMed, BMC Gastroenterol)
This study provides clinical characteristics of patients with PSIL. Thicker intestinal wall and aneurismal dilation detected on CT scan and deeper ulcer on DBE examination helps to establish a diagnosis of DLBCL.
Retrospective data • Journal
|
CRP (C-reactive protein)
|
LDH elevation
5d
Recent advances in canonical versus non-canonical Ca2+-signaling-related anti-apoptotic Bcl-2 functions and prospects for cancer treatment. (PubMed, Biochim Biophys Acta Mol Cell Res)
We also argue how some cancers, with the major focus on diffuse large B-cell lymphoma (DLBCL) are difficult to treat, although theoretically prime marked for Bcl-2-targeting therapeutics. Further work is needed to understand the non-canonical functions of Bcl-2 also at organelles beyond the mitochondria, the interaction partners outside the Bcl-2 family as well as their ability to target or exploit these functions as therapeutic strategies in diseases.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 overexpression
5d
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression. (PubMed, Cancer Genet)
The findings suggest more frequent alterations of 11q in diffuse large B cell lymphoma (DLBCL)/HGBCL-GC BCL2-, in comparison to cases of Burkitt lymphoma (BL) or DLBCL-GC BCL2+, and confirm a low genomic complexity score of BL. Variability identified in patterns of 11q alterations suggests genomic array studies may afford value over FISH testing as we continue to understand HGBCL-11q as a distinct entity, and interrogate cases of DLBCL/HGBCL-GC BCL2-.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
7d
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking. (PubMed, Technol Health Care)
Berberine, quercetin, epiberberine and palmatine, the active components of Coptis chinensis, have great potential for improving rituximab-resistant DLBCL via PIK3CG. This study revealed biomarkers and Coptis chinensis-associated molecular functions for rituximab-resistant DLBCL.
Journal
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
Rituxan (rituximab)
7d
Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma. (PubMed, Cancer Biomark)
The newly developed signature involving GOP1, GPX2, SLC7A5, ATF4, and CXCL2 has the potential to serve as a prognostic biomarker. Furthermore, our results provide additional support for the contribution of ferroptosis to DLBCL.
Journal
|
SLC7A5 (Solute Carrier Family 7 Member 5) • ATF4 (Activating Transcription Factor 4) • GPX2 (Glutathione peroxidase 2 (gastrointestinal))
7d
Lactate dehydrogenase A is implicated in the pathogenesis of B-cell lymphoma through regulation of the FER signaling pathway. (PubMed, Biofactors)
Treatment with E260, a FER inhibitor, significantly reduced the metabolism, proliferation and invasion of Raji cells. In summary, our findings highlight that LDHA plays multiple roles in B-cell lymphoma pathogenesis via FER pathways, establishing LDHA/FER may as a potential therapeutic target.
Journal
|
LDHA (Lactate dehydrogenase A)
|
LDH elevation
7d
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (clinicaltrials.gov)
P1, N=10, Terminated, Amgen | Completed --> Terminated; Amgen decided to discontinue study because of a business decision and not because of safety reasons
Trial termination
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
AMG 562
8d
Enrollment open • CAR T-Cell Therapy
|
cyclophosphamide • bendamustine • fludarabine IV
8d
Trial primary completion date
|
cyclophosphamide • NKX019
8d
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=69, Recruiting, Barbara Ann Karmanos Cancer Institute | Phase classification: P1b/2 --> P1/2 | N=44 --> 69 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Rituxan (rituximab) • Xpovio (selinexor)
8d
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
P1/2, N=49, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
cyclophosphamide • Zolinza (vorinostat) • cyclosporine
8d
Combination of theoretical analysis and experiments: Exploring the role of PLA2G7 in human cancers, including renal cancer. (PubMed, Heliyon)
Treatment with a PLA2G7 gene inhibitor (darapladib) significantly decreased the viability of ACHN and 786-O cell lines. Additionally, we observed an association between PLA2G7 mRNA levels and various drug sensitivity. Our study suggests that PLA2G7 has the potential to serve as a valuable biomarker and therapeutic target for cancer, particularly in the context of renal cancer.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
8d
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=10, Recruiting, Shanghai Ming Ju Biotechnology Co., Ltd. | Trial primary completion date: Dec 2023 --> Apr 2024
Trial primary completion date • CAR T-Cell Therapy
|
Carteyva (relmacabtagene autoleucel)
8d
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov)
P2, N=49, Recruiting, Barbara Ann Karmanos Cancer Institute | Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2025
Trial completion date • Trial primary completion date • Combination therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq) • methylprednisolone sodium succinate
9d
Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma. (PubMed, Mol Cancer Ther)
We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MALT1 (MALT1 Paracaspase)
|
Venclexta (venetoclax)
9d
High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T-cell therapy. (PubMed, Mol Ther)
Fibroblasts and vascular endothelial cells resided much closer to tumor cells in patients with poor response and short remission after CAR T therapy. Our work comprehensively and systematically dissects the relationship between cell composition, state, and spatial arrangement in the DLBCL microenvironment and the outcomes of CAR T-cell therapy, which is beneficial to predict CAR T therapy efficacy.
Clinical data • Journal • CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
10d
Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma. (PubMed, Sci Rep)
In conclusion, this study utilizing a high throughput genetic approach demonstrated that the PMS could serve as a prognostic predictor in DLBCL patients. Furthermore, the identification of the key signaling pathways for disease progression also provides information for further investigation to gain more insight into novel drug-resistant mechanisms.
Retrospective data • Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
10d
Selective deletion of E3 ubiquitin ligase FBW7 in VE-cadherin-positive cells instigates diffuse large B-cell lymphoma in mice in vivo. (PubMed, Cell Death Dis)
We conclude that selective deletion of E3 ubiquitin ligase FBW7 in VE-cadherin positive endothelial cells instigates diffuse large B-cell lymphoma via upregulation of BCL6 stability. In addition, the mice with endothelial cell-specific deletion of Fbw7 provide a valuable preclinical platform for in vivo development and evaluation of novel therapeutic interventions for the treatment of DLBCL.
Preclinical • Journal
|
BCL6 (B-cell CLL/lymphoma 6) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDH5 (Cadherin 5)
|
FBXW7 deletion
10d
Dbl family RhoGEFs in cancer: Different roles and targeting strategies. (PubMed, Biochem Pharmacol)
In this review, the common and distinctive structures of Dbl family members are discussed, and their roles in cancer are summarized with a focus on Ect2, Tiam1/2, P-Rex1/2, Vav1/2/3, Trio, KALRN, and LARG. Significantly, the strategies targeting Dbl family RhoGEFs are highlighted as novel therapeutic opportunities for cancer.
Review • Journal
|
RAS (Rat Sarcoma Virus) • TIAM1 (TIAM Rac1 Associated GEF 1) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
11d
Insulin-like Growth Factor II mRNA-binding Protein 3 is a Highly Sensitive Marker for Intravascular Large B-cell Lymphoma: Immunohistochemical Analysis of 152 Pathology Specimens From 88 Patients. (PubMed, Am J Surg Pathol)
However, of the 40 negative control samples, IMP3-positive non-germinal center B cells were detected in only 2 samples (P= 0.0131) and no intravascular IMP3-positive B cells suspicious for IVLBCL were identified. Altogether, IMP3 immunohistochemistry is a highly sensitive marker of IVLBCL and can be a helpful adjunct for IVLBCL diagnosis.
Journal
|
PAX5 (Paired Box 5) • IGF2 (Insulin-like growth factor 2)
11d
Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma. (PubMed, Leuk Lymphoma)
It can also improve the abnormal DLBCL microenvironment in which immune escape occurs, and inhibit immune escape. This study provides a new therapeutic idea for the exploration of individualized precision therapy for patients with malignant lymphoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
PD-1 expression • HAVCR2 expression • NOTCH1 expression
|
Epidaza (chidamide)
11d
Trial primary completion date • Combination therapy
|
Rituxan (rituximab) • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
11d
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov)
P=N/A, N=144, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=240 --> 144 | Trial primary completion date: Jun 2028 --> Feb 2024
Enrollment closed • Enrollment change • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)
11d
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS (clinicaltrials.gov)
P2, N=55, Recruiting, Mayo Clinic | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection
11d
Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma. (PubMed, Cancer Genet)
Novel targeted drugs may provide opportunities for patients with NUP98::PRRX1 to undergo allo-HSCT. However, since the cases of carrying the NUP98::PRRX1 are limited, more patients with this genetic change need to be investigated to elucidate the prognostic significance.
Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • PRRX1 (Paired Related Homeobox 1)
|
KRAS mutation • Chr del(7q)
12d
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy. (PubMed, Int J Mol Sci)
The results showed that patients who achieved complete response after standard-of-care immunochemotherapy and were alive and disease-free after 12 months of follow-up but had elevated sCD163 levels (above median) at diagnosis presented a significantly worse overall survival compared to those with initial serum sCD163 levels below the median (p = 0.03). Consequently, serum sCD163 levels in patients with DLBCL may constitute a marker of long-term response to chemoimmunotherapy.
Journal • IO biomarker
|
CD163 (CD163 Molecule)
|
CD163 elevation
12d
Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL. (PubMed, Biomed Pharmacother)
The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a typical cure rate of 50-70%. In this review, we elucidate ferroptosis mechanisms, its role in DLBCL, and the potential therapeutic targets in DLBCL. This review offers novel insights into the application of ferroptosis in treatment strategies for DLBCL.
Review • Journal
|
FASN (Fatty acid synthase)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine